Treatment of locally advanced low rectal cancer

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Rectal cancer is a formidable disease with high recurrence and metastasis rates, particularly before total mesorectal excision (TME) was first described by Heald and Ryall in 1982. Through this ground-breaking operative procedure, rectal cancer has become a potentially curable condition. Traditional abdominoperineal resection has gradually been replaced with TME and coloanal anastomosis for resectable low rectal cancer. In addition, improved overall survival and decreased local recurrence rates have been achieved. For locally advanced (cT3/4, cN1/2) low rectal cancer (lower tumor margin < 6 cm above the anal verge), sphincter preservation is a major concern in cancer treatment. Randomized controlled trials have shown that neoadjuvant chemoradiation therapy (CRT) leads to a decrease in tumor size and enhances the likelihood of tumor resectability and sphincter preservation with low local recurrence rates. Therefore, neoadjuvant CRT followed by TME is the standard treatment guideline used worldwide for patients with low rectal cancer. However, one must understand the basic principles of TME to know why this procedure should be employed to treat locally advanced low rectal cancer. We therefore performed a minireview to explore how surgeons address this problem, how to help patients live longer, and how to reduce the occurrence of perioperative morbidities.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalFormosan Journal of Surgery
Volume49
Issue number3
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Rectal Neoplasms
Neoadjuvant Therapy
Recurrence
Neoplasms
Therapeutics
Operative Surgical Procedures
Anal Canal
Randomized Controlled Trials
Guidelines
Neoplasm Metastasis
Morbidity
Survival

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

@article{1a6d3d55a32846cfa9ca7c99aa441202,
title = "Treatment of locally advanced low rectal cancer",
abstract = "Rectal cancer is a formidable disease with high recurrence and metastasis rates, particularly before total mesorectal excision (TME) was first described by Heald and Ryall in 1982. Through this ground-breaking operative procedure, rectal cancer has become a potentially curable condition. Traditional abdominoperineal resection has gradually been replaced with TME and coloanal anastomosis for resectable low rectal cancer. In addition, improved overall survival and decreased local recurrence rates have been achieved. For locally advanced (cT3/4, cN1/2) low rectal cancer (lower tumor margin < 6 cm above the anal verge), sphincter preservation is a major concern in cancer treatment. Randomized controlled trials have shown that neoadjuvant chemoradiation therapy (CRT) leads to a decrease in tumor size and enhances the likelihood of tumor resectability and sphincter preservation with low local recurrence rates. Therefore, neoadjuvant CRT followed by TME is the standard treatment guideline used worldwide for patients with low rectal cancer. However, one must understand the basic principles of TME to know why this procedure should be employed to treat locally advanced low rectal cancer. We therefore performed a minireview to explore how surgeons address this problem, how to help patients live longer, and how to reduce the occurrence of perioperative morbidities.",
author = "Po-Chuan Chen and Jenq-Chang Lee",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.fjs.2016.02.003",
language = "English",
volume = "49",
pages = "83--88",
journal = "Formosan Journal of Surgery",
issn = "1682-606X",
publisher = "Elsevier BV",
number = "3",

}

Treatment of locally advanced low rectal cancer. / Chen, Po-Chuan; Lee, Jenq-Chang.

In: Formosan Journal of Surgery, Vol. 49, No. 3, 01.06.2016, p. 83-88.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of locally advanced low rectal cancer

AU - Chen, Po-Chuan

AU - Lee, Jenq-Chang

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Rectal cancer is a formidable disease with high recurrence and metastasis rates, particularly before total mesorectal excision (TME) was first described by Heald and Ryall in 1982. Through this ground-breaking operative procedure, rectal cancer has become a potentially curable condition. Traditional abdominoperineal resection has gradually been replaced with TME and coloanal anastomosis for resectable low rectal cancer. In addition, improved overall survival and decreased local recurrence rates have been achieved. For locally advanced (cT3/4, cN1/2) low rectal cancer (lower tumor margin < 6 cm above the anal verge), sphincter preservation is a major concern in cancer treatment. Randomized controlled trials have shown that neoadjuvant chemoradiation therapy (CRT) leads to a decrease in tumor size and enhances the likelihood of tumor resectability and sphincter preservation with low local recurrence rates. Therefore, neoadjuvant CRT followed by TME is the standard treatment guideline used worldwide for patients with low rectal cancer. However, one must understand the basic principles of TME to know why this procedure should be employed to treat locally advanced low rectal cancer. We therefore performed a minireview to explore how surgeons address this problem, how to help patients live longer, and how to reduce the occurrence of perioperative morbidities.

AB - Rectal cancer is a formidable disease with high recurrence and metastasis rates, particularly before total mesorectal excision (TME) was first described by Heald and Ryall in 1982. Through this ground-breaking operative procedure, rectal cancer has become a potentially curable condition. Traditional abdominoperineal resection has gradually been replaced with TME and coloanal anastomosis for resectable low rectal cancer. In addition, improved overall survival and decreased local recurrence rates have been achieved. For locally advanced (cT3/4, cN1/2) low rectal cancer (lower tumor margin < 6 cm above the anal verge), sphincter preservation is a major concern in cancer treatment. Randomized controlled trials have shown that neoadjuvant chemoradiation therapy (CRT) leads to a decrease in tumor size and enhances the likelihood of tumor resectability and sphincter preservation with low local recurrence rates. Therefore, neoadjuvant CRT followed by TME is the standard treatment guideline used worldwide for patients with low rectal cancer. However, one must understand the basic principles of TME to know why this procedure should be employed to treat locally advanced low rectal cancer. We therefore performed a minireview to explore how surgeons address this problem, how to help patients live longer, and how to reduce the occurrence of perioperative morbidities.

UR - http://www.scopus.com/inward/record.url?scp=84971668214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971668214&partnerID=8YFLogxK

U2 - 10.1016/j.fjs.2016.02.003

DO - 10.1016/j.fjs.2016.02.003

M3 - Review article

AN - SCOPUS:84971668214

VL - 49

SP - 83

EP - 88

JO - Formosan Journal of Surgery

JF - Formosan Journal of Surgery

SN - 1682-606X

IS - 3

ER -